Navigation Links
Addex Achieves Statistically Significant Outcome in Phase IIa,Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease

N = 11 % time pH>4 in 24h 96.5 92.8 0.014 (Primary endpoint) % time pH>4 nocturnal 96.3 90.3 0.0028 Total duration reflux 40 86 0.0132 pH<4 24h (min) Total duration reflux 16.2 48.6 0.0021 pH<4 nocturnal (min) No. symptomatic 1.9 7.0 0.031 episodes Duration symptomatic 5.2 13.9 0.031 episodes (min)

Professor Jan Tack, Professor of Medicine at the Department of Pathophysiology, Gastroenterology Section of the University of Leuven, Belgium, commented: "In spite of the clinical successes of acid-suppressive therapy, there remains a significant unmet need in our ability to manage symptoms of GERD disease. To overcome limitations of acid-suppressive drugs, which eliminate only the acid component of reflux disease, drugs that inhibit reflux events are needed. These results, in keeping with previous animal studies, provide the first confirmation that mGluR5 inhibition is able to significantly reduce reflux events and symptoms in GERD patients. The magnitude of the effect on reflux time and symptoms suggest a potential for ADX10059 to become a major addition to our therapeutic options in GERD."

"ADX10059 is the first compound with this mode of action to have demonstrated significant therapeutic potential in GERD in man," said Dr Vincent Mutel, CEO of Addex. "Brought into clinical trials exactly 2 years after its discovery, it has the potential to become a breakthrough therapy in the management of this very common condition for which there is an important unmet medical need."

About GERD

GERD is estimated to affect 15% of the adult population in the US. The proton pump inhibitors (PPIs) are the market leaders, with annual worldwide sales of approximately $16 billion. Their mechanism of action in GERD is indi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine
2. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
3. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
4. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
7. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
8. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
Post Your Comments:
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... Surgical Company (Nasdaq: STAA ), the leading ... today announced that the Visian Implantable Collamer® Lens (ICL) ... leading ophthalmologists at meetings prior to and during the ... Surgeons (ESCRS) held in Paris, France from September 4 ...
... Present at the Rodman & Renshaw Annual Global... -- SHENZHEN, China, Sept. 8 /PRNewswire-Asia/ -- ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 2STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 3STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 4STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 5STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 6Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 2Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 3Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 4Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 5Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 6Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 7
(Date:7/12/2014)... The "North American ... Market by Angioplasty Balloon (Plain/Old, Cutting), ... IVC Filter (Retrievable), Endovascular Stent Graft ... studies the major market drivers, restraints, ... Canada. , Browse 108 market data ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Tylenol ... continue to move forward in the federal multidistrict ... of Pennsylvania, Bernstein Liebhard LLP reports. According to ... Judge Lawrence F. Stengel has ordered the deposition ... Judge Stengel found that the witness’s testimony concerning ...
(Date:7/12/2014)... ON Canada (PRWEB) July 12, 2014 Sean Francis, ... for throwing out special challenges to his clients. He’s also known ... Club. He recently found a way to combine the two and ... has raised $2,000 for the Boys and Girls Club. , The ... Program, which started on June 23rd. Francis sent out emails and ...
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 For those ... are bodies can readily absorb the nutrients in food. The ... particles that are small enough to be absorbed by human ... team, a lack of enzymes in regular food is the ... a product that was started by Michelle DelPresto, a mother ...
(Date:7/12/2014)... Utah (PRWEB) July 12, 2014 Utah ... types of startups, with awards being bestowed to companies ... spotlighted Utah’s outstanding entrepreneur community with recognition for new ... sustainable model with incoming revenue. , 25 Under 5 ... the state that are under 5 years old. Award ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2
... A nontoxic nanoparticle developed by Penn State researchers is ... both therapeutic drugs and the fluorescent dyes that can ... of Nano Letters , an interdisciplinary group of ... calcium phosphate particles ranging in size from 20 to ...
... late adulthood, the number of patients with Alzheimer,s disease (AD) ... , A team of national researchers, led by Emory ... cognitive impairment (MCI) often the earliest stage of AD. ... Journal of Alzheimer,s Disease . , The study shows ...
... Author/Therapist Provides New Resource So Families of ,Bad, Children Can ... ORMOND BEACH, Fla., Nov. 18 The holidays ... the stress of the season can foster difficult, even disorderly ... outbursts can destroy a family gathering and leave parents asking, ...
... 18 Women who have decided that they do ... sterilization. Patients who opt for hysteroscopic sterilization need to ... and return to daily activities, also consists of 2 ... (HSG). Both parts of the procedure must be performed ...
... a drug rehab program does not mean they have ... recovery and return to addiction and abuse soon after. ... the patient?" Usually it,s their family and ... counterattack these situations by offering family weekends four times ...
... innovative, cost-effective medical devices, announces immediate availability of an economical ... designed to bring affordable cytology to any size laboratory. ... ... EON) November 18, 2008 -- The NuView System does ...
Cached Medicine News:Health News:Nontoxic nanoparticle can deliver and track drugs 2Health News:Nontoxic nanoparticle can deliver and track drugs 3Health News:New approach to screen individuals for early Alzheimer's disease 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 3Health News:C.A.R.E. Florida Launches Family Weekends to Help on That Long Road to Recovery 2Health News:C.A.R.E. Florida Launches Family Weekends to Help on That Long Road to Recovery 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: